Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Accrued research and development expenditure

Other financials

Income statement

See full
Revenue-—
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0×0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept smmt:AccruedResearchAndDevelopmentCurrent.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's accrued research and development expenditure.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's accrued research and development expenditure?
Summit Therapeutics (SMMT) reported accrued research and development expenditure of $42.45M in Q1 2026.
How has Summit Therapeutics's accrued research and development expenditure changed year-over-year?
Summit Therapeutics's accrued research and development expenditure increased by 127.9% year-over-year, from $18.63M to $42.45M.
What is the long-term trend for Summit Therapeutics's accrued research and development expenditure?
Over 2 years (2023 to 2025), Summit Therapeutics's accrued research and development expenditure has grown at a 107.9% compound annual growth rate (CAGR), from $7.29M to $31.5M.